MiNK Therapeutics, Inc. (6Q40)

Overview

MiNK Therapeutics, Inc. is a pioneering biopharmaceutical firm focused on the forefront of cancer and immune-mediated disease treatment. Operating from its base in New York, New York, MiNK Therapeutics leverages its expertise in the field of invariant natural killer T (iNKT) cell therapies. As a clinical-stage enterprise, its dedication lies in advancing these innovative therapies from discovery through to commercialization. Initially known as AgenTus Therapeutics, Inc., the company underwent a rebranding to better align with its focused approach towards iNKT cell therapies. Since its establishment in 2017, MiNK Therapeutics has been an integral part of the Agenus Inc. family, benefiting from the parent company's vast resources and expertise in the biopharmaceutical sector.

Products and Services

• AGENT-797

At the core of MiNK Therapeutics’ product line is AGENT-797, a groundbreaking allogeneic iNKT cell therapy. This off-the-shelf therapeutic candidate stands out for its application in treating a plethora of myeloma diseases and solid tumors. Currently in Phase 1 clinical trials, AGENT-797 exemplifies MiNK Therapeutics’ commitment to unleashing the potential of iNKT cell therapies across various disease spectrums. Its development underscores the company's aim at delivering novel, effective treatments that can transform the therapeutic landscape for cancer and other immune-mediated diseases.